论文部分内容阅读
目的研究一种新的凋亡抑制蛋白(Inhibitor of Apoptosis Proten,IAP)livin两种异构体livin-α和livin-βmRNA在膀胱移行细胞癌(Transitional Cell Carcinoma of Bladder,TCC)组织中的表达,及其与TCC的病理分级、临床分期的相关性。方法采用逆转录聚合酶链反应(RT-PCR)法检测30例TCC患者的肿瘤组织、3例良性前列腺增生症(Benign Prostatic Hyperplasia,BPH)和2例外伤所致的膀胱破裂患者的膀胱组织中livin-α和livin-βmRNA的表达。结果30例TCC组织中livin mRNA表达阳性率为16.7%,其表达阳性的病例病理分级均为Ⅲ级,肿瘤均侵及深肌层。而3例BPH患者和2例膀胱破裂患者的膀胱组织livin mRNA表达均呈阴性。结论livin可作为TCC的分子标记物,可成为对TCC恶性程度和预后判断的参考指标。
Objective To study the expression of livin-α and livin-β mRNA of two livin isoforms of livin in Transitional Cell Carcinoma of Bladder (TCC), a new inhibitor of apoptosis protein (IAP) And its correlation with pathological grade and clinical stage of TCC. Methods The tumor tissues of 30 TCC patients, 3 benign prostatic hyperplasia (BPH) and 2 bladder rupture patients with bladder rupture were detected by reverse transcription-polymerase chain reaction (RT-PCR) livin-α and livin-β mRNA expression. Results The positive expression rate of livin mRNA in 30 TCC tissues was 16.7%. The positive expression rates of livin mRNA were all grade Ⅲ. The tumors invaded deep muscularis. However, livin mRNA expression was negative in 3 cases of BPH and 2 cases of bladder rupture. Conclusion livin can be used as a molecular marker of TCC, which can be used as a reference index to judge the degree of malignancy and prognosis of TCC.